Regeneron Pharmaceuticals, Inc.
NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
Last updated:
Abstract:
The present disclosure relates to IL2 agonists with improved therapeutic profiles.
Status:
Application
Type:
Utility
Filling date:
31 Mar 2022
Issue date:
14 Jul 2022